Cost-effectiveness of vaccination against pneumococcal infection of adults at risk within the federal and regional programs

The aim. of the work was to evaluate the cost-effectiveness of vaccination with the 13-vaIent pneumococcal conjugate vaccine (PCV13) and its combination with the 23-valent pneumococcal polysaccharide vaccine (PPV23) of immunocompetent adult patients with different levels of risk of pneumococcal infection.

Material and methods. Cost-effectiveness analysis was carried out by a modeling method, with a horizon of 15 years from the position of the healthcare system, and. taking into account the social perspective. The analysis was performed, for 20, 40, and 60 year oId patients with 1, 2, and 3 risk factors. In accordance with national recommendations, the vaccination. regimen included, the introduction, of PC 1 dose of PPV23 one year later. In addition, the analysis was performed, for vaccination, with 1 dose of PCV13.

The efficacy of PCV13 and PPV23 in different age groups corresponded, to the results of foreign studies, taking into account the data of a Russian study of the serotypic landscape of pneumococci with community-acquired, pneumonia, which required, hospitalization.

The cost of treating pneumococcal infections was calculated. on the basis of the mandatory medical insurance rates in St. Petersburg for 2019. The cost of vaccination, for federal programs was calculated, on the basis of the PCV13 price of 1199 rubles per dose, and. for regional programs — 1518.63 rubles per dose. The cost of PPV23 in both, cases corresponded. to the weighted average price of auctions for 2019 (1639 rubles per dose).

Indirect costs were calculated, on the basis of data on average wages in the Russian Federation, and. employment of citizens of various age groups.

Costs and. life expectancy were discounted, at 3.5% per year.

Results. The number of cases of infection prevented, and. the amount of costs averted, increase with increasing risk level. Moreover, with age, the number of deaths caused, by these diseases increases significantly. The volume of prevented, direct medical and. general costs per 1 vaccinated, patient varies from 0.41-2.95 thousand, rubles and. 1.00-6.82 thousand, rubles, respectively. Vaccination, of patients with 3 risk factors is most cost-effective.

Conclusion. When analyzed, from the perspective of the healthcare system., vaccination, against pneumococcal infection with PCV13+PPV23 in 60-year-old. patients with at least 1 risk factor and. patients of any age with at least 2 risk factors can be considered as cost-effective. Vaccination with 1 dose of PCV13 of patients of any age with at least 1 risk factor in the analysis from the perspective of the healthcare system, can be considered, as a cost-effective intervention.

1. Shea K. Rates of Pneumococcal Disease in Adults With Chronic Medical Conditions Pneumococcal Disease in Adults [Text] / K. Shea, J. Edelsberg, D. Weycker, et al. // OFID. 2014. - P. 1-9.

2. Kuchenbecker U., Chase D., Reichert A., Schiffner-Rohe J., Atwood M. Estimating the cost-effectiveness of a sequential pneumococcal vaccination program for adults in Germany // PLoS ONE 2018; 13(5): e0197905.

3. Morton, J. B. Risk stacking of pneumococcal vaccination indications increases mortality in unvaccinated adults with Streptococcus pneumoniae infections [Text] / J. B. Morton., H. J. Morrill, K. L. LaPlante, A. R. Caffrey // Vaccine. 2017. V.35.-№13.-P. 1692-1697.

4. Ewig S. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality [Text] / S. Ewig, N. Birkner, R. Strauss, R. Schaefer, et al. // Thorax. 2009.- V. 64.- P. 1062-1069.

5. Federal'nyj centr gigieny i epidemiologii.- Svedeniya ob infekcionnyh i para-zitarnyh zabolevaniyah.- Forma 2.

6. CHuchalin A.G. Federal'nye klinicheskie rekomendacii po vakcinoprofilaktike pnevmokokkovoj infekcii u vzroslyh [Tekst] / A.G. CHuchalin, N.I. Briko, S.N. Av-deev i dr. // Pul'monologiya. 2019.- T. 29.- №1.- S. 19-34.

7. Chen J. Cost-Effectiveness of Pneumococcal Vaccines for Adults in the United States [Text] / J. Chen, M. O'Brien, H. Yang, et al. // Adv Ther. 2014.- V. 31.- P. 392-409.

8. Lobzin YU.V. Serotipy Streptococcus pneumoniae, vyzy-vayushchih vedushchie nozologiche-skie formy pnevmokok-kovyh infekcij [Tekst] / YU.V. Lobzin, S.V. Sidorenko, S.M. Harit i dr. // ZHurnal infektologii. 2013.- T. 5.- №4.- S. 36-42.

9. Mangen, M.-J. Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands [Text] / M.-J. Mangen, M. Rozenbaum, S. Huijts, et al. / // Eur. Respir. J.- 2015.46.- P. 1407-1416.

10. Protasov A.D. Vybor optimal'noj taktiki vakcinacii protiv pnevmokokkovoj infekcii s immunologicheskih i klinicheskih pozicij u pacientov s hronicheskoj obstruktivnoj bolezn'yu leg-kih [Tekst] / A.D. Protasov, M.P. Kostinov, A.V. ZHestkov // Terapevticheskij arhiv. 2016.- T. 88.- № 5.- S. 62-69.

11. Protasov A.D. Analiz otdalennyh rezul'tatov effek-tivnosti i formirovaniya adaptivnogo immuniteta pri primenenii raznyh preparatov i skhem vakcinacii protiv pnevmokokkovoj infekcii u bol'nyh s hronicheskoj obstruktivnoj bolez-n'yu leg-kih [Tekst] / A.D. Protasov, A.V. ZHestkov, M.P. Kostinov i dr. // Terapevti-cheskij arhiv. 2017.- T. 12.-№ 2.- S. 165-174.

12. Protasov A.D. Otdalennye rezul'taty klinicheskoj ef-fektivnosti raznyh skhem vakcinacii protiv pnevmokokkovoj infekcii i vozmozhnyj mekhanizam dejstviya vakcin u bol'nyh bronhial'noj astmoj [Tekst] / A.D. Protasov, A.V. ZHestkov, M.P. Kostinov i dr. // Pul'monologiya. 2018. T. 28.- № 2.- S. 193-199.

13. Protasov A. Microbiological effect of anti-pneumococcal vaccination in COPD patients. [Text] / A. Protasov, M. Kosti-nov, A. Zhestkov // Paper presented at: 10th International Symposium On Pneumococci and Pneumococcal Diseases; June 26th - 30th, 2016; Glas-gow, UK.

14. Rukovodstvo po klinicheskoj immunologii v respirator-noj medicine [Tekst] / Pod red. M.P. Kostinova, A.G. CHucha-lina. 1-e izd. M.: ATMO.2016. -128 s.

15. Sposob formirovaniya immunologicheskoj pamyati k an-tigenam Streptococcus pneu-moniae u pacientov s hroniches-koj obstruktivnoj bolezn'yu legkih [Tekst]: Patent na izobrete-nie № 2544168. Protasov A.D., ZHestkov A.V., Kostinov M.P. i dr. 2015.- 6 s.

16. Sposob aktivacii faktorov protivovirusnoj zashchity u pacientov s hronicheskoj obstruktivnoj bolezn'yu legkih [Tekst]: Patent na izobretenie № 2600838. Protasov A.D., Kostinov M.P. 2016.- 8 s.

17. Vakcinaciya vzroslyh s bronholegochnoj patologiej: Ru-kovodstvo dlya vrachej [Tekst] / Pod red. M.P. Kostinova. M.: Art studiya «Sozvezdie». 2013.-112 c.

18. Baranov A.A. Vakcinoprofilaktika pnevmokokkovoj infekcii u detej [Tekst] / A.A. Baranov, L.S. Namazova-Barano-va, N.I. Briko i dr. // Pediatricheskaya farmako-logiya. 2018.-T.15.- № 3.- S. 200-211.

19. Kostinov M.P. Ozhidaemye epidemiologicheskij i klin-icheskij effekty vakcina-cii protiv pnevmokokkovoj infekcii v Rossii [Tekst] / M.P. Kostinov, T.N. Elagina, N.N. Filatov, A.M. Kostinova // Infekcionnye bolezni. 2018.- T. 7.- № 2.- S. 107114.

20. Ignatova G.L. Individual'naya zashchita i populy-acionnyj effekt - dva storony od-noj medali [Tekst] / G.L. Ignatova, V.N. Antonov, M.P. Kostinov, M.P. Protasov // Medi-cinskij sovet. 2018.- № 15.- S. 102-109.

21. Ignatova G.L. Vliyanie vakcinoprofilaktiki na kachestvo zhizni i prognosticheskie indeksy u bol'nyh hronicheskoj obstruktivnoj bolezn'yu legkih [Tekst] / G.L. Igna-tova, V.N. Antonov // Pul'monologiya. 2016.- № 4.- S. 473-480.

22. Rudakova A.V. Vakcinaciya vzroslyh protiv pnevmokokkovoj infekcii v rossij-skoj federacii: social'nye i farmak-oekonomicheskie aspekty [Tekst] / A.V. Rudakova, N.I. Briko, YU.V. Lobzin i dr. // ZHurnal infektologii. 2018.- T. 10.- № 3.-S. 11-22.

23. Kostinov M.P. Novye predstavleniya o terapevtiches-kom dejstvii kombinacii vak-cin protiv pnevmokokkovoj, gemofil'noj tipa b infekcii i grippa u bol'nyh hronicheskoj obstruktivnoj bolezn'yu legkih [Tekst] / M.P. Kostinov, A.V. ZHestkov, A.D. Protasov i dr. // Terapevticheskij arhiv. 2015. - T.87. - № 3. - S. 17-22.

24. Protasov A.D. Vliyanie kompleksnoj vakcinacii protiv pnevmokokkovoj, gemo-fil'noj tipa V infekcij i grippa na klin-icheskoe techenie hronicheskoj obstruk-tivnoj bolezni legkih [Tekst] / A.D. Protasov, A.A. Ryzhov, A.V. ZHestkov, M.P. Ko-stinov // Vestnik sovremennoj klinicheskoj mediciny. 2012. -T.5. - № 2. - S. 22-24.

25. Immunoprofilaktika pnevmokokkovyh infekcij. Ucheb-no-metodicheskoe posobie [Tekst] / Pod red. N. I. Briko - M.-2013.- 278 s.

26. Cilloniz C. Seasonality of pathogens causing community-acquired pneumonia [Text] / C. Cilloniz, S. Ewig, A. Gabarrus, et al. // Respirology. 2017.- V. 22.- P. 778 — 785.

27. Cilloniz C. Impact of age and comorbidity on cause and outcome in community-acquired pneumonia [Text] / C. Cilloniz, E. Polverino, S. Ewig, et al. // Chest. 2013.- V. 144.- P. 999-1007.